AN2 Therapeutics reports FY2025 net loss of $35.2M; $40M private placement extends runway into 2029

AN2 Therapeutics, Inc.

Net loss for FY2025 was $35.2 million, compared to $51.3 million in FY2024.
Cash and investments at Dec 31, 2025: $60.0 million; private placement in March 2026 added ~$40 million gross.
Phase 2 study of oral epetraborole in polycythemia vera to begin 3Q26; data readouts possible from 4Q26.
Phase 2 investigator-initiated trial in M. abscessus lung disease enrollment expected 1Q26; topline late 2027.
Phase 1 first-in-human trial of AN2-502998 for Chagas nearing completion; initial data expected 1Q26.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AN2 Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2025.

Period: fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 17, 2026, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter ended December 31, 2025.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-110681

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.